Oral Boldine Administration Attenuates Glia Activation and Prevents Neuropathic Pain in a Murine Spared Nerve Injury Model
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (Arcadia Science)
Abstract
Chronic pain is present in about 20% of the population and is a major burden to the health care system. About 30-40% of these patients report neuropathic pain. Neuropathic pain is defined as pain caused by injury or disease of the somatosensory nervous system. Current available treatments for neuropathic pain have limited efficacy and substantial side effects. To address the need for more effective and safer treatments for neuropathic pain, this study aimed to test whether boldine, a naturally occurring alkaloid, could attenuate neuropathic pain in a murine model of spared nerve injury (SNI). We found that oral administration of boldine at 50 mg/kg body weight/day resulted in significant reduction of SNI-induced mechanical and thermal hypersensitivity. Boldine also corrected SNI-induced weight bearing deficits, which are an indication of spontaneous pain. Boldine significantly inhibited SNI-induced peripheral inflammation as indicated by reduced levels of inflammatory cytokines/chemokines in the serum. Immunofluorescence studies revealed that boldine reduced the number of reactive astrocytes and inhibited microglia activation in the dorsal horn of lumbar spinal cord. Boldine also reduced the mRNA level of pro-inflammatory markers including IL-1β and TNF-α in the lumbar spinal cord after SNI. Quantitative PCR showed that boldine inhibited the lipopolysaccharide-induced overexpression of inflammatory markers in primary mouse astrocytes and in BV-2 microglial cells. Our findings suggest that boldine may be a promising therapeutic candidate for the treatment of neuropathic pain, possibly through inhibition of glia activation and neuroinflammation.
Article activity feed
-
microglia-specific connexin-43(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
Is there a reason you also wouldn't look at an astrocyte-specific Cx-43 knockout? In brain, this is the major connexin that forms gap junctions across the astrocyte syncytium. I'm also wondering whether it would be informative to do the immunostaining above (Fig 4) for Cx-43 since good antibodies exist.
-
Boldine inhibited glia activation in the lumbar spinal cord dorsal horn.
Thanks for the interesting study about a naturally derived molecule and potential for addressing an unmet clinical need. For this experiment implicating inhibition of glial activation in after boldine treatment, I think the results would be more robust with the addition of 1) immuno-staining for control glial or other histological markers that would not be expected to change with differential levels of glial activation, and 2) quantification of the fluorescence across conditions for the markers shown here (and those controls) for all animals in each group, to allow the readers to see the variance in the data across animals.
-
